ОСНОВНІ АСПЕКТИ ПАТОГЕНЕЗУ ГАСТРОДУОДЕНОПАТІЙ, АСОЦІЙОВАНИХ ІЗ НЕСТЕРОЇДНИМИ ПРОТИЗАПАЛЬНИМИ ПРЕПАРАТАМИ, У ХВОРИХ НА ОСТЕОАРТРОЗ

L Honcharuk; A. Piddubna; M. Andrushchak; H. Semko; L. Kochurka

doi:10.30888/2663-5712.2022-16-01-004

Authors

L Honcharuk Bukovinian State Medical University https://orcid.org/0000-0002-5761-1238
A. Piddubna Bukovinian State Medical University
M. Andrushchak Bukovinian State Medical University
H. Semko Bukovinian State Medical University
L. Kochurka Bukovinian State Medical University

DOI:

https://doi.org/10.30888/2663-5712.2022-16-01-004

Keywords:

nonsteroidal anti-inflammatory drugs, osteoarthritis, gastroduodenopathy.

Abstract

The largest group of users of non-steroidal anti-inflammatory drugs are patients with rheumatoid arthritis and osteoarthritis. Nonsteroidal gastropathies are diagnosed in approximately 70% of patients who systematically use these drugs. The article provi

Metrics

Metrics Loading ...

References

Rekalov D.H., Ter-Vartanian S.Kh. Osteoartroz: optymizatsiia likuvannia Za materialamy naukovo-praktychnoi konferentsii «Revmatolohichni khvoroby – suchasni problemy likuvannia ta zabezpechennia monitorynhu», 31 zhovtnia – 1 lystopada, m. Kyiv // Medychna hazeta «Zdorovia Ukrainy 21 storichchia». – 2019. - № 21 (466). - S.34-35.

Dobosh I.M., Chopei I.V., Harchar V.P. Osoblyvosti perebihu hastropatii, indukovanykh nesteroidnymy protyzapalnymy preparatamy, v osib pokhyloho viku // Medytsyna transportu Ukrainy. – 2006. - №1. – S.96-98.

Hawkey C.I. NSAIDs and gastrointestinal complications / C.I. Hawkey, N.J. Wight / LSC Life Science Communications. – London, 2001. – P. 1-56.

Svintsitskyi AS. NPZP-hastropatii: suchasnyi stan problemy // KTZh. -2010. -№2(2). – S.280-6.

Maev IV, Andreev DN, Dicheva DT, Zhilyaev EV. Novy`e predstavleniya o gastropatii, assocziirovannoj s primeneniem nesteroidny`kh protivovospalitel`ny`kh preparatov. // Consilium Medicum. – 2017. – №19 (8). -S.110–5.

Lanas A, Chan F. Peptic ulcer disease // Lancet. – 2017 - №390(10094). – Р.613-24. doi: 10.1016/S0140-6736(16)32404-7 3.

Sostres C, Marcén B, Laredo V, Alfaro E, Ruiz L, Camo P, et al. Risk of rebleeding, vascular events and death after gastrointestinal bleeding in anticoagulant and/or antiplatelet users // Aliment Pharmacol Ther. – 2019. -№50(8). – Р.919-29.

Holovach IIu. Kardiovaskuliarna bezpeka yak vazhlyvyi kryterii vyboru nesteroidnykh protyzapalnykh preparative // Mizhnarodnyi nevrolohichnyi zhurnal. – 2017. - №6(92). – S.68-74.

Parkhomenko V.V., Hopko O.F., Skrypnyk I.M. Pidvyshchennia efektyvnosti antyoksydantnoi ta tsytoprotektornoi terapii u khvorykh na npzp-hastropatiiu z suputnoiu ishemichnoiu khvoroboiu sertsia. - Aktualni problemy suchasnoi medytsyny. – 2020. - Tom 20, Vypusk 1 (69). – c.111-114.

Puzanova O.H., Svintsitskyi A.S. Hastropatiia, vyklykana vzhyvanniam nesteroidnykh protyzapalnykh preparativ: diahnostyka, profilaktyka, likuvannia // Nova medytsyna. – 2003. - №6. – S.27-30.

. Dziak H.V., Stepanov Yu.M., Hrytsenko V.I. ta in. Suchasnyi pohliad na hastropatii vyklykani nesteroidnymy protyzapalnymy preparatamy, tselekoksyb i stan sekretornoi funktsii shlunka // Suchasna hastroenterolohiia. – 2003. - №1 (11).–

S.4-11.

Tkach S.M., Sereda M.P. Sovremennыe podkhodы k profylaktyky y lechenyiu NPVP-hastropatyi // Suchasna hastroenterolohiia. – 2005. - №3. – S.66-71.

Drozdov V.N. Hastropatyy, vыzvannыe nesteroydnыmy protyvovospalytelnыmy preparatamy: patohenez, profylaktyka y lechenye // Consilium medicum. – 2005. – T7, №1. – S.3-6.

Zviahyntseva T.D., Hrydneva S.V. Sovremennыe predstavlenyia o sosudystom эndotelyy v norme y pry patolohy zheludochno-kyshechnoho trakta // Эksperymentalnaia y klynycheskaia hastroэnterolohyia. – 2005. - №4. – S.6-12.

Angiotensin II Stimulates Endothelial Vascular Cell Adhesion Molecule-1 via Nuclear Factor B Activation Induced by Intracellular Oxidative Stress / M.E. Pueyo, W. Gonzalez, A. Nicoletti [et al.] //Arteriosclerosis, Thrombosis, and Vascular Biology. - 2000. – Vol. 20. – P.645.

Cai H. Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress. /H. Cai, D.G. Harrison // Circ. Res. – 2000. – Vol.87. – P.840.

Dzau V.J. Tissue Angiotensin and Pathobiology of Vascular Disease Hypertension / V.J. Dzau // Hypertension. - 2001. – Vol. 37.- P.1047.

Pokrovskyi V.Y., Vynohradov N.A. Oksyd azota, eho fyzyolohycheskye y patofyzyolohycheskye svoistva // Terapevtycheskyi arkhyv. – 2005. - №1. – S.82-87.

In vivo study on cross talk between inducible nitric-oxide synthase and cycLooxygenase it rat gastric mucosa: effect of cyclooxygenase activity on nitric oxide prodaction / K. Uno, Y. Luchi, J. Fuji [et al.] // J. Pharmacol. Exp. Ther. – 2004. – Vol. 309, №3 – P. 995–1002.

Khattab M.M. Protective role of nitric oxide in indomethacininduced gastric ulceration by mechanism independent of gastric acid secretion / M.M. Khattab, M.Z. Gad, D. Abdallah // Pharmacol. Res. – 2001. – Vol. 43, №5, – Р. 463–467.

Cosentino F. Endothelial dysfunction in hypertension / F. Cosentino, Th. Luscher. - Milano: Grafiche Serenissima, 2003. – 52p.

Svintsytskyi A.S. Aktualni pytannia diahnostyky ta likuvannia hastropatii, zumovlenykh nesteroidnymy protyzapalnymy preparatamy // Zhurnal Zdorovia Ukrainy. – 2007. - №20/1. – S.76-77.